— Know what they know.
Not Investment Advice

ENGN NASDAQ

enGene Holdings Inc.
1W: -1.6% 1M: +5.9% 3M: +9.8% YTD: -79.7% 1Y: -71.4%
$1.80
+0.03 (+1.69%)
 
Weekly Expected Move ±7.4%
$2 $2 $2 $2 $2
NASDAQ · Healthcare · Biotechnology · Tech Score Neutral · Power 40 · $120.6M mcap · 25M float · 6.08% daily turnover · Short 41% of daily vol
Smart Money Score
Moderate 50
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$120.6M
52W Range1.4-12.25
Volume651,006
Avg Volume1,489,427
Beta-0.27
Dividend
Analyst Ratings
3 Buy 5 Hold 1 Sell
Consensus Hold
Company Info
CEORonald H. W. Cooper
Employees82
SectorHealthcare
IndustryBiotechnology
IPO Date2022-02-01
Websiteengene.com
4868 Rue Levy
Montreal, QC H4R 2P1
CA
514 332 4888
About enGene Holdings Inc.

Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.

Recent Insider Trades

NameTypeSharesPriceDate
Chinoporos Constanti 75,000 $1.75 2026-07-16
Richton Kathleen P. 0 2026-07-16
Richton Kathleen P. 45,000 $7.39 2026-07-16
Richton Kathleen P. 13,900 $9.53 2026-07-16
Richton Kathleen P. 105,000 $1.75 2026-07-16

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms